ライフサイエンスコーパス: N. gonorrhoeae

1 N. gonorrhoeae and human papillomavirus 18 (HPV18) infec

2 N. gonorrhoeae causes the sexually transmitted disease g

3 N. gonorrhoeae could also be detected from urine in coba

4 N. gonorrhoeae cultures were genotyped using multiple-lo

5 N. gonorrhoeae infection also results in the activation

6 N. gonorrhoeae is a human-restricted pathogen that prima

7 N. gonorrhoeae is able to survive the bactericidal activ

8 N. gonorrhoeae liberates a soluble factor that potently

9 N. gonorrhoeae strains that carry an inactivated msbB (a

10 N. gonorrhoeae was detected from 30 rectal and 40 pharyn

11 N. gonorrhoeae was thought to lack an SOS system, althou

12 s N. gonorrhoeae confirmation in over 13,000 N. gonorrhoeae screen-positive samples representing vari

13 We obtained 278 N. gonorrhoeae-positive isolates from 240 MSM.

14 There were 291 N. gonorrhoeae culture-positive individuals identified.

15 and 2018, the network tested 8,214 and 8,628 N. gonorrhoeae isolates, respectively, and the CDC recei

16 ike receptor 4 signaling but does not affect N. gonorrhoeae-mediated activation of the inflammasome.

17 ntracellular cIAP2 were detected early after N. gonorrhoeae stimulation, which was followed by a mark

18 Immune Abs against N. gonorrhoeae need to overcome several subversive mecha

19 found to have antimicrobial activity against N. gonorrhoeae, and Nuc expression enhanced N. gonorrhoe

20 914 has potent bactericidal activity against N. gonorrhoeae, including multidrug-resistant strains an

21 xhibited rapid bactericidal activity against N. gonorrhoeae.

22 e FDA-approved gold-containing drugs against N. gonorrhoeae.

23 ne to protect against serogroup B or against N. gonorrhoeae.

24 hyrin being the most abundant species in all N. gonorrhoeae strains studied.

25 phalosporin resistance-comprised 8.9% of all N. gonorrhoeae isolates and were primarily observed in m

26 c urethral gonorrhea, >=92.8% coverage of an N. gonorrhoeae reference genome was achieved in all samp

27 Here, we show an N. gonorrhoeae diagnostic workflow for analysis of metag

28 highest C. trachomatis prevalence (9.2%) and N. gonorrhoeae prevalence (2.2%) were in women <30 years

29 9.0%; P = 0.005), C. trachomatis (6.2%), and N. gonorrhoeae (1.4%).

30 h focused experimental data from E. coli and N. gonorrhoeae, and we validate our system's ability to

31 ion limit was 10 CFU/mL for both E. coli and N. gonorrhoeae, while commercially available gonorrhea r

32 0.61% for C. trachomatis/N. gonorrhoeae and N. gonorrhoeae/T. vaginalis, and 0.24% for C. trachomati

33 ibed here expresses both N. meningitidis and N. gonorrhoeae 16S rRNA genes, as shown by positive FISH

34 PG fragment release from N. meningitidis and N. gonorrhoeae showed that meningococci release less of

35 two pathogenic species (N. meningitidis and N. gonorrhoeae) in addition to a number of commensal spe

36 r discrimination between N. meningitidis and N. gonorrhoeae.

37 seria gonorrhoeae All vaginal microbiota and N. gonorrhoeae efficiently colonized the 3-D surface, lo

38 udies of resistance-associated mutations and N. gonorrhoeae multiantigen sequence typing, and challen

39 9 dd-peptidase, Bacillus subtilis PBP4a, and N. gonorrhoeae PBP3).

40 ested for C. trachomatis (887 specimens) and N. gonorrhoeae (890 specimens) at the Children's Hospita

41 nd (ii) swabs seeded with C. trachomatis and N. gonorrhoeae and then placed in transport medium were

42 ification (TMA) to detect C. trachomatis and N. gonorrhoeae and to determine if TMA could also detect

43 ticipants were tested for C. trachomatis and N. gonorrhoeae at three sites (anorectum, pharynx, and u

44 SDA for the detection of C. trachomatis and N. gonorrhoeae from rectal swab samples.

45 G assay (Xpert) to detect C. trachomatis and N. gonorrhoeae in rectal and pharyngeal samples from 224

46 nded for the detection of C. trachomatis and N. gonorrhoeae in swab and urine specimens of symptomati

47 omprehensive detection of C. trachomatis and N. gonorrhoeae in the pediatric population.

48 anatomic distribution of C. trachomatis and N. gonorrhoeae infection is needed to optimize future sc

49 The burden of C. trachomatis and N. gonorrhoeae infection was significantly higher in the

50 ssessed the positivity of C. trachomatis and N. gonorrhoeae infections at different anatomic sites in

51 ay influence detection of C. trachomatis and N. gonorrhoeae infections at specific anatomic testing s

52 of data on the burden of C. trachomatis and N. gonorrhoeae infections by anatomic site is lacking in

53 wn that the prevalence of C. trachomatis and N. gonorrhoeae infections is much higher in extragenital

54 antly more prevalent than C. trachomatis and N. gonorrhoeae infections, while the M. genitalium infec

55 health efforts to control C. trachomatis and N. gonorrhoeae infections.

56 women of >40 years, while C. trachomatis and N. gonorrhoeae prevalence is lowest in that age group.

57 Specimens were tested for C. trachomatis and N. gonorrhoeae using a Gen-Probe Aptima Combo 2 assay.

58 pert for the detection of C. trachomatis and N. gonorrhoeae were 86%, 99.2%, 92.5%, and 98.4% and 91.

59 148 and 154 patients for C. trachomatis and N. gonorrhoeae, respectively.

60 the clinical features of C. trachomatis and N. gonorrhoeae, the 2 organisms that drive research agen

61 lable testing options for C. trachomatis and N. gonorrhoeae.

62 the Roche assay for both C. trachomatis and N. gonorrhoeae.

63 Overall, T. vaginalis, C. trachomatis, and N. gonorrhoeae prevalences were 8.7%, 6.7%, and 1.7%, re

64 ; 95% CI, 2.1-2.7), and concurrent anorectal N. gonorrhoeae (OR, 11.4; 95% CI, 10.6-12.3).

65 Anti-E. coli or anti-N. gonorrhoeae antibodies were conjugated to submicron p

66 The objective of this work was to assess N. gonorrhoeae confirmation in over 13,000 N. gonorrhoea

67 administration of CMP-Leg5,7Ac(2) attenuated N. gonorrhoeae colonization of mouse vaginas.

68 All available N. gonorrhoeae isolates (n = 2452) received from Austral

69 onist and unveils the molecular link between N. gonorrhoeae and HIV-1.

70 and the stabilization of cleaved complex by N. gonorrhoeae gyrase increased in a fluoroquinolone-res

71 However, induction of cell death by N. gonorrhoeae has also been reported in other cell type

72 d 17 proteins important for DNA secretion by N. gonorrhoeae for protein interactions.

73 s in 1102 resistant and susceptible clinical N. gonorrhoeae isolates collected from 2000 to 2013 via

74 urethral gonorrhea can recover near-complete N. gonorrhoeae genomes.

75 The cohort comprised N. gonorrhoeae culture-positive individuals identified b

76 urs post collection, 100% yielded concordant N. gonorrhoeae culture results compared to immediate pro

77 The requirement to confirm N. gonorrhoeae in validated samples is not required for

78 c and conditioned medium from Nuc-containing N. gonorrhoeae degraded human neutrophil DNA and NETs.

79 e in populations at high risk of contracting N. gonorrhoeae induces an increase in MIC and may result

80 e in populations at high risk of contracting N. gonorrhoeae induces an increase in MIC, and may resul

81 e identification, the capacity for culturing N. gonorrhoeae in the United States has declined, along

82 We now show that msbB-deficient N. gonorrhoeae induces less inflammatory signaling in hu

83 Interestingly, infection with msbB-deficient N. gonorrhoeae is associated with less localized inflamm

84 low-passage-number clinical-specimen-derived N. gonorrhoeae isolates for Opa expression and assess th

85 ded, the sensitivity of PS testing to detect N. gonorrhoeae infections increased to 94%.

86 leic acid amplification testing would detect N. gonorrhoeae and C. trachomatis (or T. vaginalis if ut

87 ivity and specificity of Cobas for detecting N. gonorrhoeae in male urine were 100.0% (95% CI, 95.8%

88 collection of urethral discharge to diagnose N. gonorrhoeae and Chlamydia trachomatis infection in ce

89 Distinct N. gonorrhoeae transmission networks were present in a m

90 Eight N. gonorrhoeae isolates collected from 7 patients on Oah

91 We propose that Nuc enables N. gonorrhoeae to escape trapping and killing by NETs du

92 ort highlights the role for NspA in enabling N. gonorrhoeae to subvert complement despite LOS phase v

93 N. gonorrhoeae, and Nuc expression enhanced N. gonorrhoeae survival in the presence of neutrophils t

94 Gentamicin alone failed to eradicate N. gonorrhoeae from the pharynx.

95 For N. gonorrhoeae, the sensitivity of PS testing (90%) was

96 For N. gonorrhoeae, Xpert had higher sensitivity than Aptima

97 inalis detection rate compared with 2.1% for N. gonorrhoeae and 1.6% for C. trachomatis.

98 ed were >98% for C. trachomatis and 100% for N. gonorrhoeae.

99 matis infection, 0.56 [95% CI, .19-1.67] for N. gonorrhoeae infection, and 0.66 [95% CI, .38-1.15] fo

100 e agreement and 99.8% negative agreement for N. gonorrhoeae.

101 e agreement and 99.7% negative agreement for N. gonorrhoeae.

102 N. meningitidis, no vaccine is available for N. gonorrhoeae.

103 al samples represent robust biospecimens for N. gonorrhoeae NAAT testing and may not require confirma

104 etwork supported the laboratory capacity for N. gonorrhoeae AST and associated genetic marker detecti

105 tabilized the enzyme-DNA cleaved complex for N. gonorrhoeae gyrase and topoisomerase IV.

106 (78%) participants had positive cultures for N. gonorrhoeae at the time of enrollment: 24 of the 28 p

107 All patients with positive cultures for N. gonorrhoeae were cured at all sites of infection.

108 uc as a multifunctional virulence factor for N. gonorrhoeae.

109 f the beta-strands at the gate interface for N. gonorrhoeae, indicating that the gate is dynamic.

110 FU)/mL for C. trachomatis and 1500CFU/mL for N. gonorrhoeae.

111 C. trachomatis and rectum and oropharynx for N. gonorrhoeae Hence, extragenital screening is critical

112 inical urine and swab specimens positive for N. gonorrhoeae by the Cobas assay, 71% could be genotype

113 C. trachomatis, 21 (4.2%) were positive for N. gonorrhoeae, 26 (5.2%) were positive for T. vaginalis

114 This explains why the probes for N. gonorrhoeae in the Gen-Probe Aptima assays cross-reac

115 The positivity rate for N. gonorrhoeae was highest for rectal sites (10.4%), fol

116 ected specimens are comparably sensitive for N. gonorrhoeae culture.

117 and 81% sensitivity and 100% specificity for N. gonorrhoeae from isolates with a representative datab

118 nsitivity of patient-collected specimens for N. gonorrhoeae culture.

119 Repeat testing for N. gonorrhoeae was undertaken using real-time polymerase

120 tion of nucleic acid amplification tests for N. gonorrhoeae identification, the capacity for culturin

121 The sensitivity of Xpert for N. gonorrhoeae from rectal swabs was 100% (95% CI, 88 to

122 cline showed an additive effect against four N. gonorrhoeae strains, suggesting the possibility of us

123 rometry analysis of extensively fractionated N. gonorrhoeae-derived supernatants revealed that the LT

124 Deletion of amiC from N. gonorrhoeae results in severely impaired cell separat

125 doglycan O-acetyltransferase using PatB from N. gonorrhoeae as the model system.

126 BamA, the central component of BAM, was from N. gonorrhoeae, the etiological agent of the sexually tr

127 (C. trachomatis) and Neisseria gonorrhoeae (N. gonorrhoeae) infections.

128 The prevalence of mosaic PBP2 harboring N. gonorrhoeae strains highlight the ability for new N.

129 re, we report that Nuc degrades NETs to help N. gonorrhoeae resist killing by neutrophils.

130 In N. gonorrhoeae, lack of TsaP results in the formation of

131 d geographical and temporal spread of AMR in N. gonorrhoeae, and improved understanding of the pharma

132 Inhibition of cIAP2 in N. gonorrhoeae-stimulated epithelial cells resulted in i

133 en that is conserved and surfaced exposed in N. gonorrhoeae.

134 n provide reliable diagnostic information in N. gonorrhoeae infection.

135 dynamics of RMS and methylation patterns in N. gonorrhoeae.

136 L-activatable photosensitizing porphyrins in N. gonorrhoeae were identified and quantified using ultr

137 ecifically, cN supports nitrite reduction in N. gonorrhoeae strains lacking the cytochromes c5 and Cc

138 epistasis affecting antibiotic resistance in N. gonorrhoeae and a generalizable approach for epistati

139 in the level of antimicrobial resistance in N. gonorrhoeae in different settings.

140 macrolide use and azithromycin resistance in N. gonorrhoeae, finding that population-wide macrolide u

141 5,7Ac(2) and Neu5Ac9N(3) into LOS results in N. gonorrhoeae being fully serum sensitive.

142 rstand the mechanism of type IV secretion in N. gonorrhoeae, we examined the expression levels and lo

143 membrane topology, and variation of TraG in N. gonorrhoeae.

144 n antimicrobial efflux and iron transport in N. gonorrhoeae.

145 d at the radiant exposure used to inactivate N. gonorrhoeae.

146 aBL also effectively inactivated N. gonorrhoeae that had attached to and invaded into the

147 ndicated that aBL preferentially inactivated N. gonorrhoeae, including antibiotic-resistant strains,

148 We included N. gonorrhoeae isolates of patients visiting the Amsterd

149 We included N. gonorrhoeae isolates of patients who visited the Amst

150 Three strains, including N. gonorrhoeae FA1090, an nrrF deletion mutant, and a co

151 tecting several resistance threats including N. gonorrhoeae AR-Ng testing, a subactivity of the CDC's

152 epletion of human DNA with saponin increased N. gonorrhoeae yields in simulated infections but decrea

153 and mutant gene pools were transformed into N. gonorrhoeae to select for alleles that maintained bac

154 uranofin reduced the burden of intracellular N. gonorrhoeae by over 99% outperforming the drug of cho

155 t the monoglyceride monocaprin rapidly kills N. gonorrhoeae and other bacterial species and is non-ir

156 core component of most lipopolysaccharides, N. gonorrhoeae is peculiar in that it effectively libera

157 three well-defined species (N. meningitidis; N. gonorrhoeae; and Neisseria polysaccharea) and genomes

158 d identify multilocus sequence types (MLST), N. gonorrhoeae multiantigen sequence types (NG-MAST), an

159 of the cervicovaginal microbiome can modify N. gonorrhoeae, which will enhance successful transmissi

160 rhoeae strains highlight the ability for new N. gonorrhoeae strains to spread and become established

161 idis As with N. meningitidis NspA (Nm-NspA), N. gonorrhoeae NspA (Ng-NspA) bound FH/FHL-1 through FH

162 We observed N. gonorrhoeae positivity of 8.1% in the pharynx and 7.9

163 We observed N. gonorrhoeae positivity of 8.1% in the pharynx and 7.9

164 gitidis isolate described must have obtained N. gonorrhoeae-specific DNA through interspecies recombi

165 traction methods that maximize the amount of N. gonorrhoeae DNA sequenced while minimizing contaminat

166 pecially in the presence of large amounts of N. gonorrhoeae and small amounts of C. trachomatis organ

167 isR or misS severely reduced the capacity of N. gonorrhoeae to colonize mice or maintain infection ov

168 This series describes cases of N. gonorrhoeae infection among patients receiving eculiz

169 Nine cases of N. gonorrhoeae infection were identified; 8 were classif

170 negative percent agreement for detection of N. gonorrhoeae and C. trachomatis for 3 investigational

171 negative percent agreement for detection of N. gonorrhoeae and C. trachomatis for three investigatio

172 he sensitivity of Cobas for the detection of N. gonorrhoeae in female specimens was 94.8% (95% CI, 89

173 itive percent agreement for the detection of N. gonorrhoeae was 100% in both urine and swab specimens

174 ng considered for point-of-care diagnosis of N. gonorrhoeae infection or NGU in men, meatal swabs sho

175 fection and alters the infection dynamics of N. gonorrhoeae in vitro Furthermore, miR-718 regulates t

176 ly undergo apoptosis, and thus the effect of N. gonorrhoeae infection on PMN survival has implication

177 ng technology to examine the epidemiology of N. gonorrhoeae and associated AMR in the Australian popu

178 Exposure of N. gonorrhoeae to sublethal hydrogen peroxide revealed t

179 t oxygen was involved in aBL inactivation of N. gonorrhoeae.

180 acological approach, for the inactivation of N. gonorrhoeae.

181 compound library for potential inhibitors of N. gonorrhoeae PBP 2, and 32 compounds were identified t

182 hioglucose inhibited 48 clinical isolates of N. gonorrhoeae including multidrug-resistant strains at

183 fifteen clinical and laboratory isolates of N. gonorrhoeae were tested following the Clinical Labora

184 g solithromycin against clinical isolates of N. gonorrhoeae.

185 The lipooligosaccharide of N. gonorrhoeae has a hexa-acylated lipid A.

186 n simulated infections, if >=10(4) CFU/ml of N. gonorrhoeae was present, sequencing of the large majo

187 We have generated a panel of mutants of N. gonorrhoeae strain FA1090 expressing a variety of mut

188 neisserial heparin-binding antigen (NHBA) of N. gonorrhoeae and confirm its role in binding to severa

189 C model for the study of the pathogenesis of N. gonorrhoeae using a well-characterized DeltapilT muta

190 For pharyngeal gonorrhea, positivity of N. gonorrhoeae DNA on both PCR assays was present at day

191 The increasing prevalence of N. gonorrhoeae strains exhibiting decreased susceptibili

192 tial markers in the transcriptome profile of N. gonorrhoeae upon minutes of azithromycin exposure.

193 hogen mini kit provided the highest ratio of N. gonorrhoeae to human DNA and the most consistent resu

194 nerated by host innate immune recognition of N. gonorrhoeae by several innate immune signaling pathwa

195 ta suggest that TLR4-mediated recognition of N. gonorrhoeae LOS plays an important role in the pathog

196 Pre- and postmarketing safety reports of N. gonorrhoeae infection in patients receiving eculizuma

197 significantly decreased serum resistance of N. gonorrhoeae with either wild-type or truncated LOS.

198 mics in PBP2 underpins the ESC resistance of N. gonorrhoeae.

199 s undertaken to reveal which component(s) of N. gonorrhoeae induce HIV-1 expression in CD4(+) T lymph

200 arge transmission clusters (>=10 samples) of N. gonorrhoeae were susceptible to ciprofloxacin, ceftri

201 However, the specificity of N. gonorrhoeae NAATs may be suboptimal, particularly for

202 Strains of N. gonorrhoeae expressing mutant NG1686 proteins with su

203 Strains of N. gonorrhoeae that were genetically deficient in the na

204 stem (T4SS) that is found in most strains of N. gonorrhoeae.

205 creening against highly resistant strains of N. gonorrhoeae.

206 illin- or cephalosporin-resistant strains of N. gonorrhoeae.

207 IgA antibodies that bound to the surface of N. gonorrhoeae cells, as shown by indirect fluorescent a

208 aspects of the colonization and survival of N. gonorrhoeae and may be a target for new antimicrobial

209 e is critical for the growth and survival of N. gonorrhoeae in human cells.

210 n testing to determine the susceptibility of N. gonorrhoeae to ceftriaxone, cefixime, and cefpodoxime

211 cin exposure and decreased susceptibility of N. gonorrhoeae.

212 cin exposure and decreased susceptibility of N. gonorrhoeae.

213 urther, the study identifies transmission of N. gonorrhoeae between HIV-positive and HIV-negative ind

214 ustralia, we show widespread transmission of N. gonorrhoeae within and between population groups.

215 e of clinical failure following treatment of N. gonorrhoeae infections with cefixime was relatively h

216 cular, phenotypic, and epidemiologic data on N. gonorrhoeae infection could help develop a more compl

217 nificantly for C. trachomatis (P = 0.774) or N. gonorrhoeae (P = 0.163).

218 e samples (undiluted) spiked with E. coli or N. gonorrhoeae were incubated for 5 min with 1% Tween 80

219 than those for women with C. trachomatis or N. gonorrhoeae (22.3 and 21.6, respectively; P < 0.0001)

220 ater than those for Chlamydia trachomatis or N. gonorrhoeae (27.6 and 25.9 years, respectively; P < 0

221 is was more prevalent than C. trachomatis or N. gonorrhoeae in all age groups except the 18- to 19-ye

222 ting identified 92-100% of C. trachomatis or N. gonorrhoeae infections in participants assigned femal

223 AC2 assay for detection of C. trachomatis or N. gonorrhoeae was observed, although some mailed swabs

224 samples spiked with either C. trachomatis or N. gonorrhoeae, and also containing both bacteria.

225 sexual contact with either C. trachomatis or N. gonorrhoeae, or had symptoms of an STI.

226 Independent risk factors for oropharyngeal N. gonorrhoeae were assessed among MSM routinely univers

227 niversal testing detected more oropharyngeal N. gonorrhoeae infections than selective testing, of whi

228 ng of the input plasmid pools and the output N. gonorrhoeae genomic DNA pools identified mutations pr

229 However, only infection with pathogenic N. gonorrhoeae and not infection with the other bacteria

230 We performed N. gonorrhoeae cultures on paired, clinician- and patien

231 trospective cohort study of culture-positive N. gonorrhoeae infections at a single sexual health clin

232 ess the generation of antibodies recognizing N. gonorrhoeae.

233 the detection of both pharyngeal and rectal N. gonorrhoeae and C. trachomatis.

234 the detection of both pharyngeal and rectal N. gonorrhoeae and C.trachomatis.

235 bal dissemination of antimicrobial-resistant N. gonorrhoeae strains.

236 e emerging threat of antimicrobial-resistant N. gonorrhoeae.

237 nst the global threat of multidrug-resistant N. gonorrhoeae.

238 Quinolone-resistant N. gonorrhoeae and reduced cefixime susceptibility appea

239 Quinolone-resistant N. gonorrhoeae has arisen multiple times, with extensive

240 o the syndrome caused by its sister species, N. gonorrhoeae, the etiologic agent of gonorrhea.

241 clusters of patients infected with specific N. gonorrhoeae genotypes were related to various epidemi

242 ts derived from the decreased-susceptibility N. gonorrhoeae strain 35/02 and ESC-resistant strain H04

243 inhibited, although to a lesser extent than N. gonorrhoeae PriA.

244 testing studies against organisms other than N. gonorrhoeae.

245 In this study, we confirmed that N. gonorrhoeae induces production of cIAP2 in human cerv

246 These data demonstrate that N. gonorrhoeae filamentous phage can induce antibodies w

247 We demonstrate that N. gonorrhoeae msbB is dispensable for initiating and ma

248 demiological investigation demonstrated that N. gonorrhoeae infections are dominated by relatively fe

249 Our recent studies have demonstrated that N. gonorrhoeae proactively suppresses host T-helper (Th)

250 Collectively these results indicate that N. gonorrhoeae stimulation of human endocervical epithel

251 major public health concern globally is that N. gonorrhoeae is evolving high levels of antimicrobial

252 We demonstrate for the first time that N. gonorrhoeae exploits this host strategy in a novel de

253 The N. gonorrhoeae NG0969 open reading frame contains a gene

254 The N. gonorrhoeae Sequence Typing for Antimicrobial Resista

255 The N. gonorrhoeae T4SS can be grouped with F-type conjugati

256 However, disentangling the N. gonorrhoeae genome from metagenomic samples and robus

257 stablish quality control (QC) ranges for the N. gonorrhoeae ATCC 49226 control strain for MIC agar di

258 s associated with the unique function of the N. gonorrhoeae T4SS as well as generic features of F-typ

259 The sensitivity and specificity of the N. gonorrhoeae test were 100% and 100% for AC2 and 76.2%

260 ntly thicker and of greater biomass than the N. gonorrhoeae 1291 parent strain.

261 e in males was significantly higher than the N. gonorrhoeae and T. vaginalis infection rates.

262 Our studies indicate that the N. gonorrhoeae biofilm contains DNA and that the Nuc pro

263 We demonstrate that the N. gonorrhoeae RecQ helicase can bind and unwind the pil

264 ase D C-terminal" (HRDC) domain, whereas the N. gonorrhoeae RecQ helicase gene encodes three HRDC dom

265 st (muscle) cell lines was observed with the N. gonorrhoeae strain expressing PilA2.

266 This N. gonorrhoeae-derived HMP activates CD4(+) T cells to i

267 nding of FH/FHL-1 through domains 6 and 7 to N. gonorrhoeae increased with truncation of the heptose

268 We previously reported FH binding to N. gonorrhoeae independently of lipooligosaccharide (LOS

269 omplement-inhibitory activity, also binds to N. gonorrhoeae The ligand for both FH and FHL-1 was iden

270 2) administered intravaginally (10 mug/d) to N. gonorrhoeae-colonized mice were equally efficacious.

271 neutrophils released NETs after exposure to N. gonorrhoeae, but NET integrity declined over time wit

272 eculizumab dose within the 3 months prior to N. gonorrhoeae infection.

273 tection, we assessed the cross-reactivity to N. gonorrhoeae of serum raised to the meningococcal vacc

274 f PG monomers by N. meningitidis relative to N. gonorrhoeae is partly due to ampG, since replacement

275 Inflammatory responses to N. gonorrhoeae are generated by host innate immune recog

276 ction of 2,408 specimens for C. trachomatis, N. gonorrhoeae, and T. vaginalis TMA screening.

277 ve values for M. genitalium, C. trachomatis, N. gonorrhoeae, and T. vaginalis were 100, 70, 67, and 2

278 idence of any bacterial STI (C. trachomatis, N. gonorrhoeae, or M. genitalium infection) was lower in

279 matis/T. vaginalis, 0.61% for C. trachomatis/N. gonorrhoeae and N. gonorrhoeae/T. vaginalis, and 0.24

280 For the qualitative RealTime C. trachomatis/N. gonorrhoeae assay, the overall agreements between the

281 8 to 89 years old) undergoing C. trachomatis/N. gonorrhoeae screening using the Aptima Combo 2 assay

282 gests that women screened for C. trachomatis/N. gonorrhoeae, whether asymptomatic or symptomatic, sho

283 omen undergoing screening for C. trachomatis/N. gonorrhoeae.

284 e/T. vaginalis, and 0.24% for C. trachomatis/N. gonorrhoeae/T. vaginalis and highest in women <30 yea

285 Ps), and recently we reported that wild-type N. gonorrhoeae strain FA1090 has a survival advantage re

286 2.0; 95% CI, 1.9-2.1), concurrent urogenital N. gonorrhoeae (OR, 2.4; 95% CI, 2.1-2.7), and concurren

287 We used N. gonorrhoeae multiantigen sequence typing to describe

288 We used N. gonorrhoeae-spiked urine samples and samples from gon

289 Biochemical assays using N. gonorrhoeae 1291 wild type and isogenic mutant strain

290 N. meningitidis sequences, and 29 (24%) were N. gonorrhoeae sequences.

291 In considering whether N. gonorrhoeae directly influences B cells, we observed

292 The primary mechanism by which N. gonorrhoeae becomes resistant to ESCs is by acquiring

293 The mechanisms by which N. gonorrhoeae modulates cell death are not clear, altho

294 infected mice compared to mice infected with N. gonorrhoeae alone.

295 One man initially infected with N. gonorrhoeae multiantigen sequence type 2400 had type

296 ian tube epithelial cells were infected with N. gonorrhoeae, and MMP patterns were examined.

297 ine IL-8 by endocervical cells infected with N. gonorrhoeae.

298 pecies C. muridarum and then inoculated with N. gonorrhoeae following treatment with water-soluble 17

299 arum-infected mice prior to inoculation with N. gonorrhoeae concurrently with the downregulation of c

300 wever, a significant subset of patients with N. gonorrhoeae remain asymptomatic, without evidence of